High Body Mass Index Increases the Risk for Osteonecrosis in Children with Acute Lymphoblastic Leukemia
Overview
Authors
Affiliations
Purpose: The aim of the study was to determine the incidence of and clinical risk factors for radiographic osteonecrosis (ON) in children treated for acute lymphoblastic leukemia (ALL) using the Nordic ALL protocols.
Patients And Methods: Ninety-seven consecutive patients with childhood ALL were studied prospectively by magnetic resonance imaging (MRI) of the lower extremities at the end of the treatment.
Results: Twenty-three (24%) of the 97 patients had ON. Seven of the patients (30%) were symptomatic, and three patients (13%) required surgical interventions. Multiple logistic regression analysis showed that high body mass index (BMI; P = .04), female sex (P = .01), older age at diagnosis (P < .001), and higher cumulative dexamethasone dose (P = .03) were independent risk factors for radiographic ON. The cumulative prednisone dose did not differ significantly between the patients with and without ON. The incidence of radiographic ON decreased significantly, from 36% to 7%, when the duration of dexamethasone exposure during the delayed-intensification phase was shortened from 3 to 4 weeks to 2 weeks with a taper (P = .001).
Conclusion: ON as determined by MRI was found to be a common complication in children and adolescents after treatment with the Nordic ALL protocols. Revision of the ALL protocols by shortening the single exposure to dexamethasone has diminished the risk for ON remarkably. High BMI was identified as a new significant risk factor for ON.
de Winter D, Neggers S, van den Heuvel-Eibrink M, van Atteveld J Endocr Connect. 2024; 13(12).
PMID: 39437150 PMC: 11623254. DOI: 10.1530/EC-24-0487.
Mattano Jr L, Devidas M, Loh M, Raetz E, Chen Z, Winick N Leukemia. 2023; 38(2):258-265.
PMID: 38062123 PMC: 11235418. DOI: 10.1038/s41375-023-02099-1.
Extensive Osteonecrosis After Glucocorticoids: Clinical Response to Bisphosphonate.
Subbu K, Renner J, Rubin J JCEM Case Rep. 2023; 1(1):luac006.
PMID: 37908238 PMC: 10578391. DOI: 10.1210/jcemcr/luac006.
Hoo C, Leung A, Chan J, Cheung Y, Cheng F, Chow T Cancer Med. 2023; 12(9):10315-10325.
PMID: 37000036 PMC: 10225192. DOI: 10.1002/cam4.5762.
[Osteonecrosis-severe side effect of treatment for acute lymphoblastic leukemia].
Kuhlen M, Kunstreich M, Gokbuget N, Escherich G Orthopadie (Heidelb). 2022; 51(10):792-799.
PMID: 36069910 DOI: 10.1007/s00132-022-04301-1.